Full-Time
Clinical Laboratory Scientist II
Confirmed live in the last 24 hours
Guardant Health
1,001-5,000 employees
Develops blood tests for cancer diagnostics
No salary listed
Mid
Palo Alto, CA, USA
Get referrals →
You have ways to get a Guardant Health referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 2 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- California Clinical Laboratory Scientist license
- Bachelor of Arts or Science in Biomedical Laboratory Science, Clinical Science or related field
- 2+ years' experience in a clinical laboratory
- Working knowledge of local, state, and federal laboratory regulations
- Able to integrate and apply feedback in a professional manner
- Able to prioritize and drive to results with a high emphasis on quality
- Ability to work as part of a team.
- Perform laboratory tests, procedures and analyses per the laboratory’s standard operating procedures.
- Review, interpret and report patient results in LIMS.
- Independently identify and troubleshoot high complexity problems that adversely affect the test performance.
- Perform, review and document laboratory quality control procedures.
- Document all corrective actions taken when test systems deviate from the laboratory’s established performance specifications.
- Perform and document routine preventive maintenance.
- Assist with training of new laboratory personnel.
- Maintain sufficient inventory of laboratory supplies for daily operations and prepare reagents required for testing.
- Perform and document reagent qualification per the approved protocols.
- Perform annual review of Standard Operating Procedures
- Report all concerns of test quality and/or safety to the Laboratory Supervisor or Safety Officer
- Participate in introduction of assay improvements, new assay configurations and validation.
- Perform other miscellaneous laboratory duties as assigned and assist others as time allows.
Guardant Health specializes in blood-based tests that provide essential information for cancer treatment and management. Their products are designed to help patients at various stages of cancer, from early detection to managing advanced disease. The company develops and sells diagnostic tests that utilize blood samples to detect, monitor, and guide treatment decisions for cancer patients. Their main product, Guardant360, is FDA-approved and commonly used to assist in treatment decisions for those with advanced cancer. Guardant Health is also working on expanding its offerings to include tests for early-stage cancer detection and monitoring for recurrence. By focusing on non-invasive and data-rich diagnostics, the company aims to enhance patient outcomes and lessen the overall impact of cancer.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Palo Alto, California
Founded
2012
Simplify's Take
What believers are saying
- Partnerships with Pfizer and ConcertAI enhance research and therapy development capabilities.
- Growing demand for liquid biopsy tests supports Guardant Health's market expansion.
- FDA approvals bolster credibility and adoption of Guardant Health's diagnostic solutions.
What critics are saying
- Increased competition from companies like Natera may erode market share.
- Dependency on key partnerships, like with Pfizer, poses revenue concentration risks.
- Challenges in early-stage cancer detection expansion may delay revenue growth.
What makes Guardant Health unique
- Guardant Health specializes in non-invasive, blood-based cancer diagnostics.
- The company offers FDA-approved tests like Guardant360 for advanced cancer treatment decisions.
- Guardant Health integrates AI and real-world data for precision oncology solutions.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↓ -1%NEW YORK - Guardant Health said Thursday that it has entered a multiyear strategic collaboration with Pfizer, under which it will support the development and commercialization of cancer therapies using its Guardant Infinity liquid biopsy platform.
Guardant Health, a leading precision oncology company, has entered into a collaboration with ConcertAI, an oncology real-world evidence (RWD) data and AI technology company.
What You Should Know:– Guardant Health, a provider in precision oncology, and ConcertAI, a real-world evidence (RWE) and AI technology company in oncology, announced a strategic collaboration that will provide biopharmaceutical companies with access to a first-of-its-kind multi-modal real-world data (RWD) solution.– The partnership integrates comprehensive patient electronic medical record (EMR) data with genomic and epigenomic tumor profiling information, offering a deeper understanding of cancer biology and treatment response.Enhanced Cancer Research and DevelopmentCancer is a complex disease, and a patient’s response to treatment can be influenced by various factors, including specific genetic mutations, prior therapies, and the development of drug resistance. This new joint RWD solution provides critical clinical context to an extensive database of solid tumor cancer patients with multiple liquid biopsies. This allows biopharma researchers to:Better interpret disease biology: Gain a more comprehensive understanding of the underlying mechanisms driving cancer progression.Gain a more comprehensive understanding of the underlying mechanisms driving cancer progression. Identify drivers of tumor evolution: Pinpoint the specific genetic and epigenetic changes that contribute to tumor growth and spread.Pinpoint the specific genetic and epigenetic changes that contribute to tumor growth and spread. Understand resistance mechanisms: Uncover how tumors develop resistance to therapies, both intrinsically and over time.By leveraging this comprehensive dataset, combined with the analytics capabilities and AI SaaS solutions of both ConcertAI and Guardant Health, biopharmaceutical companies can gain a deeper understanding of cancer and develop more effective treatments.“Realizing the potential of precision medicine requires a comprehensive, multi-dimensional understanding of the tumor, the clinical environment and the patient’s response to therapy,” said Helmy Eltoukhy, Guardant Health co-CEO. “This partnership between Guardant and ConcertAI gives evidence and outcomes researchers access to extensive, robust data and AI-based modeling that can provide unprecedented insight into a patient’s cancer journey, including a tumor’s complex systemic interactions, to help them accelerate the development of much-needed cancer therapies
PALO ALTO, Calif.-(BUSINESS WIRE)- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
COTA Inc., a leader in real-world data (RWD) and analytics for oncology, has announced a new partnership with precision oncology company Guardant Health Inc. (Nasdaq: GH).